The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate by Lee, Shwu‑Maan et al.
Lee et al. Malar J          (2019) 18:356  
https://doi.org/10.1186/s12936-019-2989-2
RESEARCH
The Pfs230 N-terminal fragment, Pfs230D1+: 
expression and characterization of a potential 
malaria transmission-blocking vaccine 
candidate
Shwu‑Maan Lee1* , Yimin Wu1, John M. Hickey2, Kazutoyo Miura3, Neal Whitaker2, Sangeeta B. Joshi2, 
David B. Volkin2, C. Richter King1 and Jordan Plieskatt1
Abstract 
Background: Control and elimination of malaria can be accelerated by transmission‑blocking interventions such as 
vaccines. A surface antigen of Plasmodium falciparum gametocytes, Pfs230, is a leading vaccine target antigen, and 
has recently progressed to experimental clinical trials. To support vaccine product development, an N‑terminal Pfs230 
antigen was designed to increase yield, as well as to improve antigen quality, integrity, and homogeneity.
Methods: A scalable baculovirus expression system was used to express the Pfs230D1+ construct (aa 552–731), 
which was subsequently purified and analysed. Pfs230D1+ was designed to avoid glycosylation and protease diges‑
tion, thereby potentially increasing homogeneity and stability. The resulting Pfs230D1+ protein was compared to a 
previous iteration of the Pfs230 N‑terminal domain, Pfs230C1 (aa 443–731), through physiochemical characterization 
and in vivo analysis. The induction of functional antibody responses was confirmed via the standard membrane feed‑
ing assay (SMFA).
Results: Pfs230D1+ was produced and purified to an overall yield of 23 mg/L culture supernatant, a twofold yield 
increase over Pfs230C1. The Pfs230D1+ protein migrated as a single band via SDS‑PAGE and was detected by anti‑
Pfs230C1 monoclonal antibodies. Evaluation by SDS‑PAGE, chromatography (size‑exclusion and reversed phase) and 
capillary isoelectric focusing demonstrated the molecule had improved homogeneity in terms of size, conformation, 
and charge. Intact mass spectrometry confirmed its molecular weight and that it was free of glycosylation, a key 
difference to the prior Pfs230C1 protein. The correct formation of the two intramolecular disulfide bonds was initially 
inferred by binding of a conformation specific monoclonal antibody and directly confirmed by LC/MS and peptide 
mapping. When injected into mice the Pfs230D1+ protein elicited antibodies that demonstrated transmission‑reduc‑
ing activity, via SMFA, comparable to Pfs230C1.
Conclusion: By elimination of an O‑glycosylation site, a potential N‑glycosylation site, and two proteolytic cleavage 
sites, an improved N‑terminal Pfs230 fragment was produced, termed D1+, which is non‑glycosylated, homogene‑
ous, and biologically active. An intact protein at higher yield than that previously observed for the Pfs230C1 fragment 
was achieved. The results indicate that Pfs230D1+ protein produced in the baculovirus expression system is an attrac‑
tive antigen for transmission‑blocking vaccine development.
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Background
Transmission-blocking vaccines (TBVs) for malaria are 
designed to interrupt parasite transmission [1–3] and 
likely to be preferentially deployed in combination with 
other antigens targeting other life cycle stages [4, 5]. In 
human hosts, TBVs induce antibodies against sexual 
stage malaria antigens or mosquito antigens, thereby 
blocking the parasite fertilization after an Anopheles 
mosquito takes a blood meal from a parasite-infected 
individual, and thus breaking the cycle of parasite trans-
mission between human and mosquito hosts [1–3]. 
The expression and purification of the Pfs230 protein, a 
leading TBV candidate, has been challenging due to the 
large size and complexity of the protein, which is rich in 
disulfide bonds and contains multiple domains [6]. How-
ever, N-terminal fragments of Pfs230 have been success-
fully expressed in Pichia pastoris [7], in wheat germ cell 
free lysates [8], in plant [9] and in baculovirus [10]. The 
most clinically advanced Pfs230 candidate (Pfs230 D1M) 
is produced in Pichia [7] and chemically conjugated to 
Pseudomonas aeruginosa exoprotein A (EPA), a carrier 
protein demonstrated to enhance immunogenicity of the 
target antigen [11, 12]. Clinical trials are underway to test 
Pfs230-EPA in combination with GSK’s AS01 adjuvant 
[13] and initial results have been promising [Clinical-
Trail.gov Identifier: NCT02942277].
With the strong rationale and development data on 
Pfs230-based vaccines, it is important to develop con-
structs of Pfs230 that are pure and have potential for 
commercial development. The successful production 
of an N-terminal fragment of Pfs230 in the baculovirus 
expression system using super Sf9 cells was previously 
reported [10], and lessons learned from these previous 
studies was utilized to accelerate the development of a 
second-generation N-terminal Pfs230 TBV candidate. 
The prior protein, Pfs230C1 (aa 443–731), was character-
ized to be monomeric with both disulfide bonds properly 
paired and immunization of mice resulted in the induc-
tion of antibodies exhibiting transmission-reducing 
activity [10]. The production yield of Pfs230C1, however, 
was only moderate despite efforts in process optimization 
(~ 10 mg/L fermentation supernatant), and the sub-opti-
mal yield partially attributed to proteolytic degradation 
and presence of cleaved forms of Pfs230C1 [14]. Addi-
tionally, while the glycosylation was consistent between 
batches, the presence of a glycosylated form complicated 
the recombinant protein characterization [14] and over-
all product quality. Moreover, since the native parasite 
surface proteins completely lacked N- or O-glycosylation 
[15], any glycosylated forms of the recombinant protein 
do not mimic the natural target and thus are likely unde-
sirable as immunogens.
In the current study, an improved Pfs230 TBV candi-
date, Pfs230D1+, was investigated in the baculovirus 
expression system by altering the starting amino acid 
(aa 552) to avoid glycosylation and potential proteolytic 
sites. The improvement in antigen design eliminated the 
undesirable glycosylation as well as resulting in a two-
fold increase in yield and increased stability. These design 
iterations are part of a process to optimize the preclinical 
and clinical development of Pfs230-based vaccines with 
the goal of a highly effective, low cost, easily deployed 
vaccine that blocks malaria parasite transmission.
Methods
Baculovirus expression construct (Pfs230D1+)
The N-terminal sequence (aa 552–731) of the gameto-
cyte surface protein Pfs230 of 3D7 strain (ACCESSION 
P68874), containing four cysteines as part of a pre-
dicted cysteine-rich domain, was cloned and denoted 
as Pfs230D1+. Codon optimization for baculovirus 
expression was performed by DNA2.0 (now ATUM). 
Synthetic deoxynucleic acid (DNA) of Pfs230D1+ 
(552–731) contained a N585Q mutation to remove a 
potential N-glycosylation site, an N-terminal secretion 
signal (MKFLVNVALVFMVVYISYIYAD from Honey-
bee Melittin) and a C-terminal six histidine tag. Resulting 
plasmid was cloned, sequence verified, and recombinant 
bacmids generated as previously described [10]. This 
bacmid was sequence verified again and used to trans-
fect super Sf9 cells (Oxford Expression Technologies) for 
the generation of recombinant baculovirus stock using 
 Cellfectin® II reagent (Invitrogen) following Bac-to-Bac 
manual.
Expression and purification of Pfs230D1+
Super Sf9 cells were seeded at 1 × 106 cells/mL in SFM4 
medium (Hyclone). MOI (multiplicity of infection) of 
one was used to infect a 10 L super Sf9 wave culture. At 
96 h post infection, culture was harvested, concentrated 
fivefold and diafiltered with 20  mM sodium phosphate, 
150 mM NaCl, pH 7.4 (Buffer A) using a tangential flow 
filtration device (Centrasette LV, Pall) with 0.5 m2 Omega 
polyethersulfone membrane (Pall). Clarification was car-
ried out with 0.22 μm filtration (Stericup-GP vacuum fil-
ter, Merck Millipore).
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Two litres of clarified, concentrated supernatant was 
loaded onto a 61  mL (2.6 × 11.5  cm) nickel–nitrilotri-
acetic acid (Ni–NTA) (His60 Ni Superflow, Clontech) 
column at 100  cm/h. The wash steps were performed 
with five column volume (CV) of Buffer A, five CV of 
buffer A with 10  mM imidazole, then five CV of Buffer 
A with 20  mM imidazole. The protein was eluted with 
Buffer A containing 50–100  mM imidazole. Pooled 
eluents from Ni-NTA column were concentrated five-
fold with Amicon Ultra-15 centrifugal filters, using 3  K 
regenerated cellulose membrane (Merck Millipore). The 
protein was further purified, and buffer exchanged with 
size exclusion chromatography (SEC) on a Superdex 75 
(2.6 × 60 cm, 320 mL), equilibrated with 20 mM HEPES, 
150 mM NaCl, 5% glycerol, pH 7.2. To maintain a 5% CV 
injection load limit, multiple cycles were performed. The 
Superdex 75 elution fractions were evaluated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), pooled, and further concentrated to a target 
of 1  mg/mL using the same Amicon 3  K concentrator 
(Merck Millipore) and stored at − 80 °C.
Protein concentration determination
The bicinchoninic acid (BCA) assay was performed 
according to manufacturer’s instruction (Thermo) to 
determine protein concentration of purified Pfs230D1+ 
due to low tryptophan content. Bovine serum albumin 
was used to generate the protein concentration standard 
curve in the assay.
SDS‑PAGE
Samples were diluted with 4× LDS (Lithium dodecyl sul-
fate, Invitrogen) sample buffer, heated for 5 min at 90 °C 
and loaded in a final volume of 20 μL/well on SDS-PAGE 
gels (4–12% NuPAGE Bis–Tris, Invitrogen). Gels were 
run at 150–200 V for 35–50 min in 1× 2-(N-morpholino)
ethanesulfonic acid (MES) sodium dodecyl sulfate (SDS) 
running buffer and stained with SimplyBlue™ SafeStain 
(Invitrogen).
Western blotting (Anti‑His) with purified Pfs230D1+
Following SDS-PAGE, proteins were transferred onto 
nitrocellulose membrane and Western blot procedure 
using anti-penta His antibody (Qiagen) as described ear-
lier [10]. The membrane was developed using ECL Prime 
(GE Healthcare).
Western blotting using mouse anti‑Pfs230C1 monoclonal 
antibody
Mouse monoclonal antibody 15A4-1B12 was used 
to evaluate Pfs230D1+ (20  ng) via Western blot as 
described previously [14].
Capillary isoelectric focusing (cIEF)
Pfs230D1+ was incubated in either water (non-
reduced) or reduced with 10 mM dithiothreitol (DTT) 
for 30 min at 60 °C, centrifuged for 5 min at 14,000×g, 
and then subjected to cIEF using iCE280 analyzer (Con-
vergent Bioscience). Samples were run in triplicate at 
4  °C using a temperature-controlled autosampler. The 
Pfs230D1+ samples (final concentration of 50  µg/mL) 
were mixed with  Pharmalyte® 3.0–10.0 (GE Healthcare, 
final concentration of 4%), acidic and basic isoelectric 
point (pI) markers of 3.6 and 9.5 (Protein-Simple), 0.1% 
tetramethylethylenediamine, and methyl cellulose (final 
concentration of 0.35%; Protein-Simple). The samples 
were separated in 2 focusing periods, one at 1500 V for 
1 min and a second at 3000 V for 5 min.
Size exclusion‑ultra high performance liquid 
chromatography (SE‑UHPLC)
Size-exclusion-UHPLC analysis of purified Pfs230D1+ 
was performed in triplicate on a TSK-Gel BioAssist 
G25Wxl column (7.8 × 300 mm, TOSOH Biosciences, 
King of Prussia, PA) at 30  °C on a Shimadzu Promi-
nence UFLC HPLC system with a diode array detector. 
The mobile phase consisted of 20 mM HEPES, 150 mM 
NaCl, pH 7.2 with flow rate of 0.7  mL/min. A gel fil-
tration standard (Bio-Rad, Hercules, CA) was used to 
ensure column and HPLC system integrity prior to each 
set of runs. The Pfs230D1+ samples were also run with 
and without the column to determine sample recovery 
(74 ± 1% for triplicate determinations).
Reversed‑phase (RP) UHPLC
Samples of Pfs230D1+ were incubated in water (non-
reduced) or 10  mM DTT (reduced) for 30  min at 
60  °C and analysed using an Ultimate 3000 UHPLC 
system (Thermo Scientific) with an Accucore C4 col-
umn (2.6  µm, 2.1 ×  150  mm, Thermo Scientific) at a 
flow rate of 0.2 mL/min. C4 column and auto-sampler 
temperatures were set at 60  °C and 5  °C, respectively. 
The elution of Pfs230D1+ was monitored at absorb-
ance (214 nm) using a gradient that consisted of mobile 
phase (A): water with 0.1% trifluoroacetic acid (TFA) 
and mobile phase (B): acetonitrile (ACN) with 0.1% 
TFA as follows: 5  min at 1%B, 10  min 1–70%B, 1  min 
70–99%B, 1 min at 99%B, 1 min 99–1%B, and 2 min at 
1%B. The non-reduced Pfs230D1+ samples were also 
run with and without column to determine sample 
recovery (94 ± 7% for triplicate determinations). The 
recovery of the reduced sample could not be examined 
due to interference from DTT.
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Intact mass spectrometry
Pfs230D1+ was incubated in water (non-reduced) or 
10 mM DTT (reduced) for 30 min at 60 °C and desalted 
via a RP BEH C4 trap column (2.1 ×  50  mm, Waters, 
1.7  µm particles) using Agilent 1220 chromatography 
system. The intact mass of the protein (in triplicate 
experiments) was measured using a G6230B time of-
flight mass Spectrometer (Agilent Technologies). Mass 
 spectra1  (MS1) were acquired over a mass range of 
400–3200 m/z, with a scan rate of 1 spectra/s. Protein 
deconvolution was performed using MassHunter (Agi-
lent Technologies).
LC/MS peptide mapping for N‑terminal and disulfide bond 
analysis
Pfs230D1+ was incubated in water (non-reduced) or 
10 mM DTT (reduced) for 30 min at 60 °C, alkylated with 
20  mM iodoacetamide and then digested overnight at 
37 °C with chymotrypsin. The digested peptides were then 
subjected to LC/MS using a C18 column (2.1 × 150 mm, 
1.7  µm, Thermo Fisher Scientific) operated at 50  °C on 
UltiMate 3000 UHPL (Thermo Fisher Scientific). The 
mobile phases consisted of A (water + 0.05% TFA) and B 
(ACN + 0.05% TFA) and the peptides were eluted using a 
5–25% B gradient over 55 min at flow rate of 0.2 mL/min. 
Peptides were identified using a LTQ-XL ion-trap mass 
spectrometer (Thermo Fisher Scientific) in positive-ion 
mode and a mass range of 400–1900 m/z was used. Pep-
tides and disulfide bonds were identified using  MS1 and 
 MS2 data and PepFinder (Thermo Scientific). Disulfide 
bonds were also confirmed manually.
Free thiol determination
Free thiols (number of free cysteine residues) were 
measured in triplicate using Ellman’s reagent (Thermo 
Scientific) according to manufacturer’s instructions. 
Pfs230D1+ was diluted (in triplicate) in either ultrapure 
water or 1.5 M guanidine-HCl to achieve a final concen-
tration of 27 µM prior to conducting the assay. A stand-
ard curve was constructed using known concentrations 
of l-cysteine (3 to 200 µM, Millipore Sigma). Absorbance 
was measured at 412 nm.
Generation of mouse anti‑Pfs230 antiserum 
and enzyme‑linked immunosorbent assay (ELISA)
CD-1 mice, ten in each group, were immunized with 5.0, 
0.5 or 0.05  µg of purified Pfs230C1 or Pfs230D1+ pro-
tein formulated with Montanide ISA720 (ISA; Seppic, 
Fairfield, NJ) adjuvant on day 0 and 21 by intramuscu-
lar injection (Noble Life Sciences, Inc., Woodbine, MD). 
Serum samples were collected on day 42. Due to techni-
cal issues, day 42 sera were not collected from one mouse 
in 0.5  µg of Pfs230C1 group, and five mice in 0.5  µg of 
Pfs230D1+ group. A second immunization study was 
conducted using 1 µg of Pfs230C1 or Pfs230D1+ protein 
formulated with Montanide ISA 720. The immunization 
studies were conducted under an approved Noble Life 
Sciences (NLS), the Institutional Animal Care and Use 
Committee (IACUC) protocol. Noble Life Sciences is an 
Association for Assessment and Accreditation of Labora-
tory Animal Care (AAALAC), international accredited, 
United States Department of Agriculture (USDA) com-
pliant and Office of Laboratory Animal Welfare (OLAW) 
assured contract research organization.
For the day 42 sera, antibody level against correspond-
ing proteins were determined individually by ELISA. 
The basic methodology of the ELISA has been described 
[16] and the minimal detection level of the ELISA was 41 
ELISA units to both proteins.
IgG purification and standard membrane feeding assay 
(SMFA)
For each group, an equal amount of serum from each 
mouse was pooled regardless of ELISA units. Total IgGs 
from the pooled serum sample was purified using Protein 
G columns (GE Healthcare) according to the manufac-
turer’s instructions and adjusted to a final concentration 
of 4 mg/mL in phosphate buffered saline.
The standardized methodology for performing the 
SMFA has been described previously [17]. Briefly, P. fal-
ciparum NF54 line was cultured for 16–18 days to induce 
mature stage V gametocytes. The stage V gametocytes 
(~ 1% stage V gametocytaemia) were mixed with test 
IgGs at 750  µg/mL, and the final mixture was immedi-
ately fed to ~ 50 female Anopheles stephensi through a 
membrane-feeding apparatus. All feeding experiments 
were performed with human complement. Mosquitoes 
were kept for 8  days after feeding and dissected (n = 20 
per group) to enumerate the oocysts in the midgut. Only 
midguts from mosquitoes with any eggs in their ova-
ries at the time of dissection were analysed. The human 
serum and red blood cells used for the gametocyte cul-
tures and feeding experiments were purchased from 
Interstate Blood Bank (Memphis, TN).
Statistical analysis
To compare ELISA units among three dose groups in 
each immunogen, Kruskal–Wallis test was utilized, fol-
lowed by Dunn’s multiple comparisons tests. For SMFA 
results, the best estimate of   % inhibition in oocyst 
density [percentage transmission reducing activity 
(TRA)], and the p-values were calculated using a zero-
inflated negative binomial (ZINB) random effects model 
described previously [18]. All statistical tests were per-
formed in R (version 3.4.1) or Prism 7 (GraphPad).
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Results
Baculovirus produces a soluble N‑terminal domain 
of Pfs230 (Pfs230D1+)
The new design of a Pfs230  N-terminal construct con-
taining aa 552–731 was based on the previously reported 
Pfs230C1 TBV antigen (aa 443–731) [10, 14], denoted as 
Pfs230D1+, and evaluated in the super Sf9/baculovirus 
system. This design was selected to reduce the potential 
for proteolytic cleavage and glycosylation while preserv-
ing the complete disulfide-linked folding predicted to be 
required for induction of transmission-blocking antibod-
ies following immunization. Pfs230D1+ also contains an 
additional N585Q mutation to eliminate potential N-gly-
cosylation and a six histidine C-terminal tag to facilitate 
purification in the initial evaluation here. Moreover, the 
removal of N-terminal amino acids from the original 
Pfs230C1 protein did not appear to alter the predicted 
secondary structure of Pfs230D1+ as suggested by POL-
YVIEW-2D [19].
The expression of Pfs230D1+ was first evaluated with 
a MOI of 1, 3 or 5 at small-scale (25 mL) and samples 
were taken at 48, 72 and 96 h post infection to evaluate 
protein expression. As expression level was independ-
ent of MOI, MOI of one was selected for all further 
analyses. The supernatant and pellet samples were 
analysed by reducing SDS-PAGE (Fig.  1a) and anti-
His Western blot (Fig.  1b) with no evidence of degra-
dation at 96  h post infection. Supernatant fractions 
of Pfs230D1+ showed a predominant singular band 
reactive to anti-His antibodies, while pellet fractions 
demonstrated a doublet also reactive to anti-His but 
containing a heterogeneous mixture of proteins most 
likely including misfolded protein (Fig.  1b). Therefore, 
a MOI of 1 and 96 h of the secreted supernatant frac-
tion was selected for further expression at the 10 L cul-
ture scale. Pellet fractions were not targeted for further 
development and identity of the lower band of the dou-
blet was not interrogated further.
A two-step purification approach was used to capture 
and polish Pfs230D1+ including IMAC (immobilized 
metal affinity column) and SEC and resulted in a yield 
of 23  mg/L as presented here. Further, the resulting 
purified protein was present at the expected molecular 
weight of ~ 21  kDa (kilodalton) and with greater than 
90% purity by SDS-PAGE and densitometry (Fig.  2a). 
Reactivity to anti-His antibody confirmed the presence 
of the histidine tag on the C-terminus (Fig. 2b).
Evidence for the correct disulfide conformation was 
supported by Western blot using a reduction sensitive 
conformational monoclonal antibody, 15A4-1B12 [14] 
as shown in Fig. 2c. In addition, evaluation by capillary 
isoelectric focusing revealed one major peak in the elec-
tropherogram of reduced or non-reduced Pfs230D1+ 
(Fig.  2d), confirming the presence of a major singu-
lar charged isoform. The observed pI of ~ 5.9 for the 
reduced form and ~ 6.2 for the non-reduced form were 
close to the theoretical pI of 5.6 for Pfs230D1+ based 
on the protein’s amino acid sequence.
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Fig. 1 Expression of Pfs230D1+ in super Sf9 cells. a Reduced SDS‑PAGE and b anti‑His Western blot analysis of pellets (P) and supernatant (S) 
samples of Pfs230D1+ in super Sf9 cell (MOI of 1) at 48, 72, and 96 h post infection with uninfected control (U) at 72 h. Molecular weight marker (M) 
and an irrelevant His‑tagged protein used as a positive control for Western blot (Ctrl) are indicated for lane labels. Supernatant (S) fractions show 
a predominant singular band (and later targeted for purification) while pellet (P) fractions demonstrate a doublet band, both cellular fractions are 
reactive to anti‑His antibodies (b)
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Chromatographic analysis of purified D1+
Analytical SE-UHPLC was performed to assess the 
solution state of the purified recombinant protein. 
Pfs230D1+ eluted as a single peak near the reten-
tion time of the 17  kDa SEC standard protein, which 
was close to the expected size of monomer ~ 21.3  kDa 
(Fig.  3a). Recovery across the SEC column was ~ 74%; 
indicating additional higher MW species may be pre-
sent in the sample. A single peak was also observed by 
RP-UHPLC under non-reducing or reducing conditions 
(Fig.  3b, c), indicating the recombinant protein was 
structurally homogeneous and > 95% pure.
Intact mass and peptide mapping
The intact mass analysis indicated that the observed 
masses of non-reduced (21,321.9 ± 0.0  Da) and reduced 
(21,326.1 ± 0.0 Da) forms of Pfs230D1+ were similar to 
their theoretical values of 21,321.3  Da and 21,325.3  Da, 
respectively (Fig.  4). In addition to the main species, 
higher mass species were observed under non-reducing 
(21,478.2 ± 0.0  Da) and reducing (21,482.6 ± 0.1  Da) 
conditions. These two species are + 156 Da higher than 
the mass of Pfs230D1+ based on the primary sequence, 
which corresponded to the presence of an additional Arg 
residue.
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Fig. 2 Electrophoresis of purified Pfs230 D1+. a SDS‑PAGE and b anti‑His Western blot analysis. c Western blot analysis of Pfs230D1+ using 
mouse monoclonal antibody 15A4‑1B12. Lanes are labeled as follows: Pre‑stained molecular weight markers (M); non‑reduced samples (NR), 
reduced samples (R), an irrelevant His‑tagged protein used as a positive control for Western blot (Ctrl). d Representative cIEF electropherograms of 
Pfs230D1+. A single peak was observed for reduced (~ 5.9) and non‑reduced Pfs230DI+ (~ 6.2), which were close to the theoretical pI of 5.6. The 
reported averages ± 1SD were calculated from three independent experiments
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LC/MS peptide mapping was used to confirm the 
Pfs230D1+ primary sequence and identify the location 
of the additional Arg residue (Fig. 5). Primary sequence 
coverage for non-reduced or reduced chymotrypsin-
digested Pfs230D1+ was 84% or 91%, respectively 
(Fig.  5b). In the chymotrypsin-digested, reduced and 
alkylated Pfs230D1+ peptide chromatogram (Fig.  5a 
top), peaks at ~ 57.8  min and ~ 63.8  min were identified 
as the N-terminal peptide with or without an additional 
Arg residue (Table 1). The presence of the additional Arg 
residue was confirmed using  MS1 (Fig. 5c) and  MS2 data. 
The relative ion abundance of the additional Arg residue 
was 19 ± 2% compared to the N-terminal peptide without 
the additional Arg. Finally, no glycans were detected by 
intact mass analysis or LC/MS peptide mapping, indicat-
ing Pfs230D1+ was free of glycosylation as a result of the 
mutation strategy and N-terminal truncation.
Analysis of disulfide bonds
To determine if the four cysteine residues in Pfs230D1+ 
formed disulfide bonds within the protein, the number of 
exposed thiol groups was measured using Ellman’s rea-
gent. The results indicated Pfs230D1+ contained < 3% 
free thiol, under both native and denatured conditions 
(1.5  M guanidine hydrochloride), which suggested that 
the four cysteines were likely disulfide paired.
Disulfide mapping using LC/MS was employed to 
determine the disulfide pairing of the four cysteine resi-
dues  (Cys593,  Cys611,  Cys626, and  Cys706) in Pfs230D1+. 
Using the peptides from the non-reduced chymotrypsin 
digestion, disulfide bonds were identified between  Cys593 
and  Cys611 and between  Cys626 and  Cys706 (Table  2). 
Alternative disulfide bonds or free cysteine residues were 
not observed. A schematic representation of the amino 
acid sequence of Pfs230D1+ and the elucidated disulfide 
mapping is provided in Fig.  6. This observed disulfide 
pairing for Pfs230D1+ matched the predicted bonding 
pattern of the cysteine-rich motif [6].
Short‑term stability study
To support the stability during the various manipula-
tions and analyses reported here, a short-term stabil-
ity study was conducted for the purified recombinant 
Pfs230D1+. After storage at 24  °C or 4  °C for 7  days, 
no sign of aggregation or degradation via SDS-PAGE 
(Fig.  7) was observed. Further, the Pfs230D1+ protein 
was evaluated after three additional freeze–thaw cycles, 
with no changes observed (Fig.  7). These initial stud-
ies were designed and developed to support the use and 
manipulation of Pfs230D1+ during the feasibility and 
evaluation stage. The stability studies for Pfs230D1+ will 
be expanded as the preclinical development program 
continues.
Immunological evaluation of Pfs230D1+
To determine whether the Pfs230D1+ protein could 






























Fig. 3 UHPLC analysis of purified Pfs230D1+. Representative 
a SE‑UHPLC and b RP‑UHPLC (reduced and non‑reduced) 
chromatogram of purified Pfs230D1+ with inset zoom (c). Blue traces 
are non‑reduced and black traces are reduced samples
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Pfs230C1 [10], two independent immunization studies 
were performed. Study #1 consisted of CD-1 outbred 
mice immunized with Pfs230C1 or Pfs230D1+ pro-
teins at 5.0, 0.5 or 0.05  µg doses emulsified in Monta-
nide ISA720 adjuvant. When antibody reactivity was 
assessed by ELISA against the corresponding immu-
nogen (Fig.  8a), both proteins were immunogenic and 
showed clear dose responses (p = 0.001 for Pfs230C1, 
and p = 0.015 for Pfs230D1+ groups by Kruskal–Wallis 
tests). The functionality of antibodies was evaluated by 
SMFA (Fig. 8b, Table 3). When purified total IgGs were 
tested at 750  µg/mL in the presence of complement, 
all IgGs showed significant inhibitions (> 84%TRA, 
p < 0.001 for all study #1 samples as shown in Table 3). 
A second immunization study at the 1  µg dose with 
Montanide 720 for both proteins was then performed 
to confirm the functional activities observed. Here, 
in the second study, both anti-Pfs230C1 and anti-
Pfs230D1+ purified IgGs also showed significant 
inhibitions (> 98% TRA, p < 0.001 for both, shown in 
Table  3). These results demonstrated that Pfs230D1+ 
recombinant protein could reproducibly elicit biologi-
cally active antibodies.
Discussion
The baculovirus expression system was utilized pre-
viously to produce a soluble monomeric N-terminal 
domain of Pfs230, termed Pfs230C1 (aa 443–731) [10]. 
It was concluded that this protein was properly folded 
as it contained the appropriate paired disulfide bonds 
and produced functional antibodies in mice. However, 
there was a low level of O-glycosylation present which 
would not be expected in the parasite produced Pfs230 
protein. Using peptide mapping and LC/MS/MS, one 
of the glycosylation sites was identified as serine (aa 
551). The present study was aimed to improve the 
Pfs230C1 construct by further truncating the N-termi-
nal fragment of Pfs230C1 and originating the sequence 
at valine (aa 552), the amino acid after the O-glyco-
sylation site. The intact mass analyses, coupled with 
the LC/MS peptide mapping indicated that the dual 
strategy of sequence mutation (N585Q) coupled with 
the abbreviated N-terminus of Pfs230D1+ (originating 
at aa 552) eliminated any glycosylation propensity, and 
resulted in a more pure and more homogeneous mol-
ecule than Pfs230C1 [10].
Tachibana et al. produced 30 recombinant Pfs230 frag-
ments across the full-length Pfs230 molecule using wheat 
+ 156.3 Da
+ 156.5 Da
Counts vs. Deconvoluted Mass (amu)
Non-Reduced
Reduced
Fig. 4 Intact mass analysis of purified Pfs230D1+ (non‑reduced and reduced). Representative deconvoluted mass spectra of non‑reduced and 
reduced Pfs230D1+. Inset shows zoom of 21,321.0 Da (non‑reduced) and 21,326.1 Da (reduced) corresponding to theoretical masses of 21,321.3 Da 
and 21,325.3 Da, respectively. Mass additions with second species originating of ~ + 156 Da corresponds to additional N‑terminal Arg residue as 
confirmed by LC/MS peptide mapping (Fig. 5). The reported averages ± 1SD were calculated from three independent experiments
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germ cell free expression system, five fragments of which 
elicited transmission-blocking activities and all of them 
contained cysteine motif 1 (CM 1) [20]. The results from 
the present study are consistent with this observation 
[20], as the D1+ fragment (aa 552–731) encompasses the 
entire functionally active CM1 domain (aa 589–730).
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620        630        640        650        660        670 
CEVKVNEPLI KVKIICPLKG SVEKLYDNIE YVPKKSPYVV LTKEETKLKE KLLSKLIYGL 
680        690        700        710        720        730 
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Non-reduced and chymotrypsin-digested Pfs230DI+ chromatogram
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Fig. 5 LC/MS peptide mapping of Pfs230D1+. a Reduced (top) and non‑reduced (bottom) chymotrypsin‑digested Pfs230D1+ base‑peak ion 
chromatograms. b Sequence coverage of reduced or non‑reduced chymotrypsin‑digested Pfs230D1+ was 91% and 84%, respectively. c In the 
chymotrypsin‑digested Pfs230DI+ base‑peak ion chromatogram, peaks at ~ 57.8 min and ~ 63.8 min correspond to the N‑terminal peptide with 
or without an additional Arg residue (+ 156 Da) on the N‑terminus, respectively. The relative ion abundance of the N‑terminal peptide containing 
the N‑terminal Arg residue was 19 ± 2%, which was determined from six experiments (three independent non‑reduced or reduced chymotrypsin 
digestions)
Table 1 Confirmation of partial N-terminal arginine addition
Peptide Calculated monoisotopic mass Observed monoisotopic mass Mass 
differences 
(Da)














Table 2 LC/MS analysis of disulfide linked peptides from non-reduced Pfs230D1+
Time m/z MS area Charge Avg mass Peptide Disulfide linkage
50.3 1390.1 5671.8 3 4167.2 A583‑L619 Cys593 to  Cys611
46.6 788.4 35,737.6 4 3149.6 V592‑L599/K600‑L619
50.8 1566.4 63,264.2 2 3130.5 V592‑L619
60.4 959.4 2012.4 4 3833.7 I620‑L628/Y703‑Y726 Cys626 to  Cys706
52.8 1175.3 3364.4 3 3522.5 I620‑L628/I705‑Y726
58.0 918.5 1964.2 4 3669.9 I620‑L628/F704‑Y726
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In parallel to the studies conducted here, a shorter 
Pfs230 fragment (aa 589–731, encompassing the entire 
CM1 domain alone) was also analysed. This CM1 protein 
was expressed at substantially lower levels (5  mg/mL) 
and failed to induce antibodies with functional activity 
when tested alongside the longer D1+. These results sug-
gest that the 37 amino acids leading to CM1 (present in 
the D1+ construct) are important for the folding of CM1 
domain thereby allowing for better expression/secretion. 
It should also be noted that Pfs230D1+ is similar to the 
Pichia produced Pfs230D1M (aa 542–736), which is 
functionally active and encompasses the CM1 domain 
[7]. The critical traits for Pfs230D1M, such as the over-
all production yield, the glycosylation profile, as-well-as 
the presence of potential protease sites in the construct 
sequence have not been reported [7]. A direct biochemi-
cal or biological comparison between Pfs230D1+ and 
Pfs230D1M was not made in the studies reported here.
Correct disulfide bond formation within recombi-
nant proteins is important to maintain native epitopes 
and ensure induction of functional antibodies; herein 
evidence was provided that the appropriate intramo-
lecular disulfide bonds and conformations are present 
in the Pfs230D1+ protein. A conformational monoclo-
nal antibody, 15A4-1B12 that was previously reported 
[14] to be reactive to the CM1 domain was used to probe 
Pfs230D1+. The results indicated positive reactivity in a 
reduction sensitive manner. Further analysis by peptide 
mapping with chymotrypsin digests confirmed the cor-
rect disulfide bond formation of the four cysteines pre-
sent in Pfs230D1+.
Approximately 19% of the recombinant Pfs230D1+ 
contains an additional N-terminal arginine as determined 
by intact mass analysis and LC/MS peptide mapping. 
This arginine is not part of the signal peptide from Hon-
eybee Melittin as signal peptide cleavage occurs at the 
C-terminal  Ala21 [21, 22]. The same super Sf9 insect cells 
have previously been used to clone and express other 
Plasmodium antigens [10, 23], resulting in good fidelity; 
therefore, this is unlikely to be the reason for the arginine 
addition. Since the protein was expressed via a secretory 
pathway in insect cells, the inclusion of an N-terminal 
Asp residue of the signal peptide was not unexpected and 
has previously been reported [10, 23]; however, Arg addi-
tion was not found in the recombinant Pfs25 or Pfs230C1 
560        570        580        590        600        610 
DVGVDELDKI DLSYETTESG DTAVSEDSYD KYASQNTNKE YVCDFTDQLK PTESGPKVKK 
620        630        640        650        660        670 
CEVKVNEPLI KVKIICPLKG SVEKLYDNIE YVPKKSPYVV LTKEETKLKE KLLSKLIYGL 
680        690        700        710        720        730 
LISPTVNEKE NNFKEGVIEF TLPPVVHKAT VFYFICDNSK TEDDNKKGNR GIVEVYVEPY 
731
G--HHHHHH
Fig. 6 Disulfide pairing of Pfs230D1+ as experimentally confirmed by LC/MS peptide mapping. Pfs230D1+ contains four Cys residues  (Cys593, 
 Cys611,  Cys626, and  Cys706). Using the peptides from the non‑reduced chymotrypsin digest, disulfide bonds were identified between  Cys593–Cys611 
and  Cys626–Cys706. Alternative disulfide bonds or free Cys residues were not observed
M  NR  R  NR  R   NR  R  NR  R














Fig. 7 Short‑term stability study. Purified Pfs230D1+ was subjected 
to 24 °C or 4 °C treatment for 7 days or freeze–thaw (F/T) for 
three cycles at − 70 °C. Samples were run on SDS‑PAGE under 
non‑reducing (NR) and reducing conditions (R) alongside untreated 
control (Ctrl). M: molecular weight marker; 24 °C for 7 days; 4 °C for 
7 days; Three freeze/thaw cycles
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expressed in baculovirus [10, 23]. As a non-His tagged 
variant of Pfs230D1+ in the baculovirus system is being 
developed, additional information about the N-terminal 
Arg addition may be gained.
The final purified yield for Pfs230D1+ without optimi-
zation was 23  mg/L culture, more than twofold higher 
than achieved for Pfs230C1 [10, 14]. This yield improve-
ment was attributed to, at least in part, the improved sta-
bility of the Pfs230D1+ antigen. In the current analysis of 
Pfs230D1+, the cleavage products were not observed as 
was seen during optimization of the process for Pfs230C1 
[14]. Two of the proteolytic sites identified (via N-ter-
minal sequencing) for Pfs230C1 as C-terminal to  Arg541 
and  Gln545, are not present in Pfs230D1+. MacDonald 
et al. [7] also observed a consistent cleavage C-terminal 
to  Arg541 in the Pichia expression system when they 
attempted to express a Pfs230 fragment encompasses aa 
444 to 736. Their solution to this issue is similar to that 
reported here in that Pfs230D1M starts at the amino 
acid after the cleavage site,  Ser542 with N585Q mutation 
to mitigate N-glycosylation; however, a second potential 
protease site  (Gln545) as well as the potential O-glycosyla-
tion site  (Ser551) remains in the Pfs230D1M construct 
and its glycoprotein profile was not reported. Prelimi-
nary, short-term stability studies conducted thus far 
with Pfs230D1+ (Fig. 7) did not show any degradation or 
cleaved forms under the conditions tested. Further accel-
erated studies (including 37 °C) are planned.
Conclusions
In this study, the theoretical (e.g. glycosylation probabil-
ity) and empirical data are combined to improve anti-
gen design, resulting in a more stable, homogeneous, 
and higher expressed TBV candidate that is biologically 
active. While facilities for baculovirus expression are 
less common than other systems (e.g. Escherichia coli or 
Pichia), some commercial vaccines [24, 25] are being pro-
duced using this system, and the data presented indicate 
it is a viable option for cGMP vaccine manufacturing.
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tested at 750 µg/mL with complement in SMFA. Oocyst count in individual mosquito (dots) and the arithmetic mean (bars) are shown with % 
transmission‑reducing activity (%TRA) calculated against control group. All inhibitions were significant (p < 0.001 for all by the ZINB model)
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